Clinical trial · Observational
Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy
NCT01454037CI-TRIAL-00008494unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The change of immune profiles and existence of circulating tumor cells following prostate cryotherapy may be correlated with the clinical outcome.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Cancer Cells | — | UNRESOLVED | — |
| Clinical Corelation | — | UNRESOLVED | — |
| Immune Profile | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostate cryotherapy | Procedure | — | UNRESOLVED |
| Radiation | Procedure | — | UNRESOLVED |
| Radical prostatectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Prostate cryoablation
- description
- Subjects receiving cryotherapy for prostate cancer
- interventionNames
- Procedure: Prostate cryotherapy
- label
- Radical prostatectomy
- description
- Subjects receiving radical prostatectomy
- interventionNames
- Procedure: Radical prostatectomy
- label
- Radiation
- description
- Subjects receiving radiation for prostate cancer
- interventionNames
- Procedure: Radiation
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Age\>20 years * Histopathology-proven prostate adenocarcinoma * Non-metastatic localized disease * Subjects have chosen their curative, definitive treatments for prostate cancer prior to enrolling for the study * Subjects are willing to sign the informed consent and agree to comply with the study procedures Exclusion Criteria: * Chronic use (\> 2 weeks) of \> 10 mg/day of prednisone or prednisolone within 2 months of the screening (topical or inhalational corticosteroids are permitted) * Concurrent use of immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry * Other conditions the investigators think may affect subjects' compliance
References
Publications (0)
Data not yet available
No reference posted for this study.